Adaptive Biotechnologies price to sales ratio ADPT

Market value divided by revenue over the last twelve months, since 2020.

Today, Oct 23, 2026: 13.2×
7-year median: 8.4×
Against its 7-year history: 68th; percentile: 0 is its lowest day, 100 its highest
7-year range: 2.0× to 100×
Peer median: 6.8×

Adaptive Biotechnologies' price to sales ratio is 13.2× as of Oct 23, 2026.

That is above its 7-year median of 8.4×, higher than on 68% of days in the last 7 years.

Over that time it ranged from 2.0× in Apr 2024 to 100× in Jan 2021.

The median for 10 biotech stocks of a similar size is 6.8×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	13.2×	6.9×	15.2×
2025	10.1×	5.4×	12.9×
2024	5.2×	2.0×	5.3×
2023	3.9×	2.8×	8.5×
2022	6.5×	5.6×	22.3×
2021	27.0×	24.4×	100×
2020	87.5×	29.3×	92.6×

Against its peers

Companies in Biotechnology nearest Adaptive Biotechnologies' size, closest first, today.

Company	Price to sales ratio
ADPTAdaptive Biotechnologies	13.2×
ADMAAdma Biologics	4.7×
VCELVericel	7.1×
KRYSKrystal Biotech	20.9×
RGENRepligen	12.7×
TECHBIO-TECHNE	9.4×
HALOHalozyme Therapeutics	8.6×
NBIXNeurocrine Biosciences	4.3×
EXELExelixis	6.6×
MGTXMeiraGTx	2.2×
INCYIncyte	4.0×
Peer median	6.8×

Where Adaptive Biotechnologies ranks

#45of 63Biotech stocks with the lowest price to sales ratio

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Adaptive Biotechnologies

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.